atenolol has been researched along with Diabetes Mellitus, Type 2 in 72 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension." | 9.41 | Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension. ( Akhtar, L; Elahi, A; Faisal, Z; Hussain, M; Javed, A; Majid, A, 2021) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a double-masked, parallel-group design, 9,193 patients with hypertension and electrocardiographic LVH were randomized to losartan- or atenolol-based antihypertensive treatment and followed for a mean of 4." | 9.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 9.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 9.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "This study demonstrates that losartan significantly improved endothelial function in type 2 diabetes patients with hypertension compared with atenolol." | 9.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| "This study was done to evaluate the effect of treatment with manidipine as compared with atenolol on thrombin-mediated platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus." | 9.11 | Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2005) |
| "As compared to atenolol, losartan treatment was associated with less peripheral vascular hypertrophy/rarefaction and higher insulin sensitivity." | 9.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "By improving glucose and lipid metabolism and reducing lipid peroxidation, carvedilol may offer advantages in patients with diabetes and hypertension." | 9.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM)." | 9.08 | Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. ( Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Van Nueten, L; Vertommen, C; Zoppi, A, 1997) |
| "With ramipril treatment urinary albumin creatinine ratio (14." | 6.68 | Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 6.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| " The purpose of this study was to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension." | 5.41 | Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension. ( Akhtar, L; Elahi, A; Faisal, Z; Hussain, M; Javed, A; Majid, A, 2021) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a double-masked, parallel-group design, 9,193 patients with hypertension and electrocardiographic LVH were randomized to losartan- or atenolol-based antihypertensive treatment and followed for a mean of 4." | 5.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen." | 5.13 | The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| " To determine whether thiazide-induced diabetes is mediated by changes in potassium, we analyzed data from 3790 nondiabetic participants in the Systolic Hypertension in Elderly Program, a randomized clinical trial of isolated systolic hypertension in individuals aged >or=60 years treated with chlorthalidone or placebo." | 5.13 | Changes in serum potassium mediate thiazide-induced diabetes. ( Appel, LJ; Klag, MJ; Miller, ER; Parekh, RS; Shafi, T, 2008) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 5.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 5.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "This study demonstrates that losartan significantly improved endothelial function in type 2 diabetes patients with hypertension compared with atenolol." | 5.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| "This study was done to evaluate the effect of treatment with manidipine as compared with atenolol on thrombin-mediated platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus." | 5.11 | Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2005) |
| "As compared to atenolol, losartan treatment was associated with less peripheral vascular hypertrophy/rarefaction and higher insulin sensitivity." | 5.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "To compare the effects of the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol (Uniloc) on insulin sensitivity and glucose and lipid homeostasis in patients with type-2 diabetes and hypertension." | 5.08 | Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients. ( Eriksson, JW; Foley, K; Jansson, PA; Lithell, H, 1996) |
| "By improving glucose and lipid metabolism and reducing lipid peroxidation, carvedilol may offer advantages in patients with diabetes and hypertension." | 5.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM)." | 5.08 | Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. ( Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Van Nueten, L; Vertommen, C; Zoppi, A, 1997) |
| "Atenolol, a first-generation β-blocker, effectively reduces blood pressure, although its use in metabolic syndrome remains controversial." | 3.77 | Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. ( Angerosa, M; Cao, G; Dominici, FP; Giani, JF; Muñoz, MC; Toblli, JE, 2011) |
| "7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients." | 3.75 | INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009) |
| "The authors conducted a clinical investigation in twenty-five patients affected with essential hypertension of mild or moderate grade associated with type II diabetes mellitus, the purpose being to assess the effect of 8 weeks of combined treatment with atenolol (100 mg) and chlorthalidone (25 mg) on arterial blood pressure, heart rate, and glycaemia." | 3.67 | Hypotensive effect of the association atenolol-chlorthalidone in hypertensive diabetics. ( Coltorti, M; Gentile, S, 1984) |
| "Atenolol treatment decreased fasting and postprandial glycerol (p < 0." | 2.77 | The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes. ( Brassard, P; Cianflone, K; Ferland, A; Lacroix, S; Méthot, J; Poirier, P; Smith, J, 2012) |
| "Most individuals with type 2 diabetes are affected by hypertension and thus have higher risk of cardiac complications." | 2.73 | Impact of beta-blocker treatment and nutritional status on glycemic response during exercise in patients with type 2 diabetes. ( Bergeron, J; Brassard, P; Croteau, S; Ferland, A; Fournier, L; Lacroix, S; Lemieux, S; Poirier, P, 2007) |
| "Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks." | 2.72 | Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006) |
| "Hypertensive patients (n = 758) with Type 2 diabetes (mean age 56 years, mean blood pressure 159/94 mmHg), 400 of whom were allocated to the angiotensin converting enzyme inhibitor captopril and 358 to the beta blocker atenolol." | 2.70 | An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). ( Adler, A; Clarke, P; Cull, C; Gray, A; Holman, R; Neil, A; Raikou, M; Stevens, R; Stratton, I, 2001) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments." | 2.69 | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. ( , 1998) |
| "1148 hypertensive patients with type 2 diabetes from UK prospective diabetes study randomised to tight control of blood pressure (n=758) or less tight control (n=390)." | 2.69 | Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. ( , 1998) |
| "With ramipril treatment urinary albumin creatinine ratio (14." | 2.68 | Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996) |
| "Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect." | 2.68 | Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. ( Bakris, GL; Copley, JB; Mangrum, A; Sadler, R; Vicknair, N, 1997) |
| "Diabetic nephropathy is characterized by hypertension and a relentless decline in kidney function." | 2.67 | Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. ( Gall, MA; Nielsen, FS; Parving, HH; Rossing, P; Skøtt, P; Smidt, UM, 1994) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 2.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "Beta blockers used for the treatment of hypertension may be associated with increased risk for new-onset diabetes mellitus (DM)." | 2.44 | A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. ( Bangalore, S; Grossman, E; Messerli, FH; Parkar, S, 2007) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.56) | 18.7374 |
| 1990's | 21 (29.17) | 18.2507 |
| 2000's | 34 (47.22) | 29.6817 |
| 2010's | 12 (16.67) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, F | 1 |
| Yang, F | 1 |
| Liang, Y | 1 |
| Li, L | 1 |
| Xia, Y | 1 |
| Jiang, F | 1 |
| Liu, W | 1 |
| Qi, Y | 1 |
| Chowdhury, SR | 1 |
| Xie, D | 1 |
| Fu, L | 1 |
| Majid, A | 1 |
| Javed, A | 1 |
| Hussain, M | 1 |
| Faisal, Z | 1 |
| Elahi, A | 1 |
| Akhtar, L | 1 |
| Cook, RF | 1 |
| Bussey, CT | 1 |
| Mellor, KM | 1 |
| Cragg, PA | 1 |
| Lamberts, RR | 1 |
| Jani, SM | 1 |
| Nallamothu, BK | 1 |
| Cooper, LT | 1 |
| Smith, A | 1 |
| Fazel, R | 1 |
| Okin, PM | 2 |
| Hille, DA | 1 |
| Wiik, BP | 2 |
| Kjeldsen, SE | 5 |
| Lindholm, LH | 2 |
| Dahlöf, B | 6 |
| Devereux, RB | 4 |
| Patel, BM | 1 |
| Bhadada, SV | 1 |
| Cooper-Dehoff, RM | 2 |
| Hou, W | 1 |
| Weng, L | 1 |
| Baillie, RA | 1 |
| Beitelshees, AL | 1 |
| Gong, Y | 1 |
| Shahin, MH | 1 |
| Turner, ST | 1 |
| Chapman, A | 1 |
| Gums, JG | 1 |
| Boyle, SH | 1 |
| Zhu, H | 1 |
| Wikoff, WR | 1 |
| Boerwinkle, E | 1 |
| Fiehn, O | 1 |
| Frye, RF | 1 |
| Kaddurah-Daouk, R | 1 |
| Johnson, JA | 1 |
| Chen, RJ | 1 |
| Chu, H | 1 |
| Tsai, LW | 1 |
| Ostergren, J | 1 |
| Poulter, NR | 2 |
| Sever, PS | 4 |
| Wedel, H | 2 |
| Beevers, G | 1 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| Kristinsson, A | 1 |
| McInnes, GT | 1 |
| Mehlsen, J | 1 |
| Nieminen, M | 1 |
| O'Brien, E | 1 |
| Shafi, T | 1 |
| Appel, LJ | 1 |
| Miller, ER | 1 |
| Klag, MJ | 1 |
| Parekh, RS | 1 |
| Escobar, C | 2 |
| Barrios, V | 2 |
| Handberg, EM | 1 |
| Mancia, G | 1 |
| Zhou, Q | 1 |
| Champion, A | 1 |
| Legler, UF | 1 |
| Pepine, CJ | 1 |
| Ghuman, N | 1 |
| Tendler, B | 1 |
| Gjertson, CK | 1 |
| Kaur, M | 1 |
| Moskowitz, H | 1 |
| White, WB | 1 |
| Larstorp, AC | 1 |
| Høieggen, A | 2 |
| Olsen, MH | 2 |
| Ibsen, H | 3 |
| Lindholm, L | 1 |
| Wachtell, K | 2 |
| Smith, J | 1 |
| Ferland, A | 2 |
| Méthot, J | 1 |
| Brassard, P | 2 |
| Lacroix, S | 2 |
| Poirier, P | 2 |
| Cianflone, K | 1 |
| Fyhrquist, F | 1 |
| Silventoinen, K | 1 |
| Saijonmaa, O | 1 |
| Kontula, K | 1 |
| de Faire, U | 1 |
| Os, I | 1 |
| Toblli, JE | 1 |
| Cao, G | 1 |
| Giani, JF | 1 |
| Muñoz, MC | 1 |
| Angerosa, M | 1 |
| Dominici, FP | 1 |
| Nerla, R | 1 |
| Di Franco, A | 1 |
| Milo, M | 1 |
| Pitocco, D | 1 |
| Zaccardi, F | 1 |
| Tarzia, P | 1 |
| Sarullo, FM | 1 |
| Villano, A | 1 |
| Russo, G | 1 |
| Stazi, A | 1 |
| Ghirlanda, G | 1 |
| Lanza, GA | 1 |
| Crea, F | 1 |
| Caro, JJ | 1 |
| Lee, K | 1 |
| Cruickshank, JM | 1 |
| Holzgreve, H | 1 |
| Nakov, R | 1 |
| Beck, K | 1 |
| Janka, HU | 1 |
| Matthews, DR | 1 |
| Stratton, IM | 1 |
| Aldington, SJ | 1 |
| Holman, RR | 1 |
| Kohner, EM | 1 |
| Mugellini, A | 3 |
| Rinaldi, A | 1 |
| Zoppi, A | 3 |
| Lazzari, P | 3 |
| Fogari, E | 1 |
| Corradi, L | 2 |
| Fogari, R | 3 |
| Fossum, E | 1 |
| Hjerkinn, E | 1 |
| Nesbitt, SD | 1 |
| Andersen, UB | 1 |
| Phillips, RA | 1 |
| Gaboury, CL | 1 |
| Julius, S | 1 |
| Carr, AA | 1 |
| Kowey, PR | 1 |
| Brenner, BM | 1 |
| Lyle, PA | 1 |
| Snapinn, SM | 1 |
| Zhang, Z | 1 |
| Edelman, JM | 1 |
| Shahinfar, S | 1 |
| Bertoluci, MC | 1 |
| Uebel, D | 1 |
| Schmidt, A | 1 |
| Thomazelli, FC | 1 |
| Oliveira, FR | 1 |
| Schmid, H | 1 |
| Saloranta, C | 1 |
| Tuomi, T | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Baumgart, P | 1 |
| Boschmann, M | 1 |
| Kreuzberg, U | 1 |
| Engeli, S | 1 |
| Adams, F | 1 |
| Franke, G | 1 |
| Klaua, S | 1 |
| Scholze, J | 1 |
| Weidinger, G | 1 |
| Luft, FC | 1 |
| Sharma, AM | 1 |
| Jordan, J | 1 |
| Savoia, C | 2 |
| Touyz, RM | 2 |
| Endemann, DH | 1 |
| Pu, Q | 1 |
| Ko, EA | 1 |
| De Ciuceis, C | 1 |
| Schiffrin, EL | 2 |
| Volpe, M | 1 |
| Flammer, AJ | 1 |
| Hermann, F | 1 |
| Wiesli, P | 1 |
| Schwegler, B | 1 |
| Chenevard, R | 1 |
| Hürlimann, D | 1 |
| Sudano, I | 1 |
| Gay, S | 1 |
| Neidhart, M | 1 |
| Riesen, W | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 1 |
| Noll, G | 1 |
| Lehmann, R | 1 |
| Narkiewicz, K | 1 |
| Oparil, S | 1 |
| Hedner, T | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Jönsson, B | 1 |
| Bangalore, S | 1 |
| Parkar, S | 1 |
| Grossman, E | 1 |
| Messerli, FH | 1 |
| Croteau, S | 1 |
| Lemieux, S | 1 |
| Bergeron, J | 1 |
| Fournier, L | 1 |
| Tomás, JP | 1 |
| Calderon, A | 1 |
| Echarri, R | 1 |
| Preti, P | 2 |
| Derosa, G | 1 |
| Gentile, S | 1 |
| Coltorti, M | 1 |
| Sasaki, H | 1 |
| Naka, K | 1 |
| Kishi, Y | 1 |
| Ohoshi, T | 1 |
| Hagihara, T | 1 |
| Matsuo, H | 1 |
| Sowa, R | 1 |
| Matsumoto, G | 1 |
| Sanke, T | 1 |
| Nanjo, K | 1 |
| Nielsen, FS | 3 |
| Rossing, P | 3 |
| Gall, MA | 3 |
| Skøtt, P | 2 |
| Smidt, UM | 3 |
| Parving, HH | 3 |
| el-Yazigi, A | 1 |
| Bouchama, A | 1 |
| al-Abdely, H | 1 |
| Yusuf, A | 1 |
| Sieck, JO | 1 |
| Schnack, C | 1 |
| Hoffmann, W | 1 |
| Hopmeier, P | 1 |
| Schernthaner, G | 1 |
| Curb, JD | 1 |
| Pressel, SL | 1 |
| Cutler, JA | 1 |
| Savage, PJ | 1 |
| Applegate, WB | 1 |
| Black, H | 1 |
| Camel, G | 1 |
| Davis, BR | 1 |
| Frost, PH | 1 |
| Gonzalez, N | 1 |
| Guthrie, G | 1 |
| Oberman, A | 1 |
| Rutan, GH | 1 |
| Stamler, J | 1 |
| Eriksson, JW | 1 |
| Jansson, PA | 1 |
| Foley, K | 1 |
| Lithell, H | 1 |
| Bakris, GL | 1 |
| Mangrum, A | 1 |
| Copley, JB | 1 |
| Vicknair, N | 1 |
| Sadler, R | 1 |
| Giugliano, D | 1 |
| Acampora, R | 1 |
| Marfella, R | 1 |
| De Rosa, N | 1 |
| Ziccardi, P | 1 |
| Ragone, R | 1 |
| De Angelis, L | 1 |
| D'Onofrio, F | 1 |
| Chen, JW | 1 |
| Sato, A | 1 |
| Lusardi, P | 1 |
| Van Nueten, L | 1 |
| Vertommen, C | 1 |
| Miser, WF | 1 |
| Greenfield, JR | 1 |
| Chisholm, DJ | 1 |
| Levinson, PD | 1 |
| Gray, A | 1 |
| Clarke, P | 1 |
| Raikou, M | 1 |
| Adler, A | 1 |
| Stevens, R | 1 |
| Neil, A | 1 |
| Cull, C | 1 |
| Stratton, I | 1 |
| Holman, R | 1 |
| Faller, J | 1 |
| Hess, B | 1 |
| Wiedermann, CJ | 1 |
| Bloom, JM | 1 |
| Stornello, M | 1 |
| Valvo, EV | 1 |
| Scapellato, L | 1 |
| Vulpis, V | 1 |
| Antonacci, A | 1 |
| Prandi, P | 1 |
| Bokor, D | 1 |
| Pirrelli, A | 1 |
| Feher, MD | 2 |
| Henderson, AD | 1 |
| Wadsworth, J | 2 |
| Poulter, C | 1 |
| Gelding, S | 1 |
| Richmond, W | 2 |
| Elkeles, RS | 2 |
| Lamey, PJ | 1 |
| Gibson, J | 1 |
| Barclay, SC | 1 |
| Miller, S | 1 |
| Fagan, SC | 1 |
| McCormick, PW | 1 |
| Diaz, FG | 1 |
| Torrens, DJ | 1 |
| Koh, H | 1 |
| Nambu, S | 1 |
| Ikeda, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema[NCT02718547] | 25 participants (Anticipated) | Interventional | 2017-03-26 | Recruiting | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects[NCT00388388] | Phase 2 | 1 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Few subjects recruited, sponsor withdrew support.) | ||
| A Double-Blind, Randomized, Parallel Design Study of Aliskiren Versus Hydrochlorothiazide in Mild-to Moderate Hypertensive Type II Diabetes Mellitus Patients on Remodeling of Resistance Arteries[NCT01480791] | Phase 2 | 0 participants (Actual) | Interventional | 2012-01-31 | Withdrawn (stopped due to Because of results of Altitude trial, this trial was cancelled.) | ||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
3 reviews available for atenolol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index; Diab | 2007 |
Beta-blockers, diabetes, and hypoglycemia: risky business?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2001 |
41 trials available for atenolol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension.
Topics: Adult; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind | 2021 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amino Acids; Atenolol; Blood Glucose; Diabetes | 2014 |
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2008 |
Changes in serum potassium mediate thiazide-induced diabetes.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Diabetes Mellitus, Type 2; | 2008 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hy | 2010 |
The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Atenolol; Complement C3; Cross-Over Studies; Diabetes | 2012 |
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2011 |
Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients.
Topics: Atenolol; Benzazepines; Brachial Artery; Cardiovascular Diseases; Cyclic Nucleotide-Gated Cation Cha | 2012 |
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Bloo | 2004 |
Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Atenolol; Cross-Over Studies; Diabetes Mellitus, Type | 2005 |
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; F | 2005 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Gluco | 2006 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blo | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; A | 2007 |
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Cross-Over Studies; Diabetes Mel | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Impact of beta-blocker treatment and nutritional status on glycemic response during exercise in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; | 2007 |
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery, | 2008 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bl | 2008 |
Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cholesterol; Diabetes | 1994 |
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Albuminuria; Apolipoproteins; Apoprotein(a); Atenolol; Blood Pressure; Circadian Rhythm; Diabetes Me | 1994 |
Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1996 |
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 1996 |
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlor | 1996 |
Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blo | 1996 |
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Black People; Blood Pressure; Calcium Channel Blockers; | 1997 |
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Ateno | 1997 |
Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Diabetes Mellitus | 1997 |
Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pres | 1997 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Confiden | 2001 |
Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.
Topics: Adult; Aged; Albuminuria; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 1992 |
[The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Glucose; Diabetes Mellitus, Ty | 1991 |
Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Topics: Adrenergic alpha-Antagonists; Aged; Atenolol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1990 |
28 other studies available for atenolol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Topics: Animals; Antigens, CD; Cell Membrane Permeability; Diabetes Mellitus, Type 2; Esters; Glucose; Human | 2019 |
β
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Diabetes Mellitus, Experimental; Dia | 2017 |
Beating, Fast and Slow.
Topics: Angina Pectoris; Atenolol; Biopsy; Bradycardia; Chest Pain; Diabetes Mellitus, Type 2; Diagnosis, Di | 2017 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease | 2014 |
Impact of Beta-Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Population-Based Cohort Study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Dat | 2017 |
Diabetes and hypertension: which is the best approach?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2009 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro | 2009 |
Radiating abdominal pain and hypertension.
Topics: 3-Iodobenzylguanidine; Abdominal Pain; Adrenal Gland Neoplasms; Aged, 80 and over; Antihypertensive | 2009 |
Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Atenolol; Benzopyrans; Blood Pressure; Diabetes Mel | 2011 |
An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 24).
Topics: Antihypertensive Agents; Atenolol; Captopril; Diabetes Mellitus, Type 2; Evaluation Studies as Topic | 2002 |
[A problem that should be recognized. Greater risk of diabetes with antihypertensive drugs?].
Topics: Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug | 2004 |
[Diabetic with hallucination].
Topics: Atenolol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2006 |
Beta-blockers as sub-optimal treatment for hypertension: time for first-line therapy revision?
Topics: Adrenergic beta-Antagonists; Aging; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diab | 2006 |
Hypotensive effect of the association atenolol-chlorthalidone in hypertensive diabetics.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Chlorthalidone; Diabetes Mellitus, Type 2; Dia | 1984 |
Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
Topics: Adult; Aged; Atenolol; Carteolol; Diabetes Mellitus, Type 2; Diltiazem; Enalapril; Female; Glucose; | 1994 |
Impaired elimination of atenolol in a nephropathic patient with self-medication overdose.
Topics: Atenolol; Diabetes Mellitus, Type 2; Drug Overdose; Female; Humans; Hypertension; Metabolic Clearanc | 1993 |
Antihypertensive therapy in type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mell | 2000 |
[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
Topics: Adult; Antihypertensive Agents; Atenolol; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Ty | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Melli | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type | 2002 |
Grinspan's syndrome: a drug-induced phenomenon?
Topics: Aged; Aged, 80 and over; Atenolol; Bendroflumethiazide; Chlorpropamide; Diabetes Mellitus, Type 2; D | 1990 |
Hemodynamic vertebrobasilar insufficiency as an adverse effect of antihypertensive therapy.
Topics: Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Enalapril; Humans; Male; Middle Aged; | 1989 |
Acute lipoprotein changes associated with atenolol therapy for hypertension in non-insulin dependent diabetes.
Topics: Adult; Aged; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Lipoproteins; Male; | 1988 |
Effect of atenolol on serum beta 2-microglobulin level in hypertensive diabetic patients.
Topics: Atenolol; beta 2-Microglobulin; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabete | 1985 |